405 related articles for article (PubMed ID: 27396477)
1. Parkinson's Disease, Diabetes and Cognitive Impairment.
Ashraghi MR; Pagano G; Polychronis S; Niccolini F; Politis M
Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):11-21. PubMed ID: 27396477
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
Nowell J; Blunt E; Gupta D; Edison P
Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease.
Jeong SH; Chung SJ; Yoo HS; Hong N; Jung JH; Baik K; Lee YH; Sohn YH; Lee PH
Brain; 2021 May; 144(4):1127-1137. PubMed ID: 33895825
[TBL] [Abstract][Full Text] [Related]
4. Repurposing GLP1 agonists for neurodegenerative diseases.
Markaki I; Winther K; Catrina SB; Svenningsson P
Int Rev Neurobiol; 2020; 155():91-112. PubMed ID: 32854860
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase 4(DPP4) inhibitors stride up the management of Parkinson's disease.
Maanvi ; Kumari S; Deshmukh R
Eur J Pharmacol; 2023 Jan; 939():175426. PubMed ID: 36544303
[TBL] [Abstract][Full Text] [Related]
6. The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease.
Cheong JLY; de Pablo-Fernandez E; Foltynie T; Noyce AJ
J Parkinsons Dis; 2020; 10(3):775-789. PubMed ID: 32333549
[TBL] [Abstract][Full Text] [Related]
7. Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes.
Brauer R; Wei L; Ma T; Athauda D; Girges C; Vijiaratnam N; Auld G; Whittlesea C; Wong I; Foltynie T
Brain; 2020 Oct; 143(10):3067-3076. PubMed ID: 33011770
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological therapy of Parkinson's disease: current options and new avenues.
Simola N; Pinna A; Fenu S
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):221-38. PubMed ID: 20726838
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance and Parkinson's disease: A new target for disease modification?
Athauda D; Foltynie T
Prog Neurobiol; 2016; 145-146():98-120. PubMed ID: 27713036
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes.
Elbassuoni EA; Ahmed RF
Neurochem Int; 2019 Dec; 131():104583. PubMed ID: 31654678
[TBL] [Abstract][Full Text] [Related]
12. Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk.
Paudel YN; Angelopoulou E; Piperi C; Shaikh MF; Othman I
Pharmacol Res; 2020 Feb; 152():104593. PubMed ID: 31843673
[TBL] [Abstract][Full Text] [Related]
13. Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
Vu TC; Nutt JG; Holford NH
Br J Clin Pharmacol; 2012 Aug; 74(2):284-95. PubMed ID: 22300470
[TBL] [Abstract][Full Text] [Related]
14. Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes.
Bayram E; Litvan I
Brain; 2020 Oct; 143(10):2868-2871. PubMed ID: 33103730
[TBL] [Abstract][Full Text] [Related]
15. Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
Cardoso S; Moreira PI
Int Rev Neurobiol; 2020; 155():37-64. PubMed ID: 32854858
[TBL] [Abstract][Full Text] [Related]
16. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
Jin Y; Zhao H; Hou Y; Song G
Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
[TBL] [Abstract][Full Text] [Related]
17. Polyphenols in Parkinson's Disease: A Systematic Review of In Vivo Studies.
Kujawska M; Jodynis-Liebert J
Nutrients; 2018 May; 10(5):. PubMed ID: 29783725
[TBL] [Abstract][Full Text] [Related]
18. Cognitive performance in mid-stage Parkinson's disease: functional connectivity under chronic antiparkinson treatment.
Vancea R; Simonyan K; Petracca M; Brys M; Di Rocco A; Ghilardi MF; Inglese M
Brain Imaging Behav; 2019 Feb; 13(1):200-209. PubMed ID: 28942477
[TBL] [Abstract][Full Text] [Related]
19. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists.
Labandeira CM; Fraga-Bau A; Arias Ron D; Muñoz A; Alonso-Losada G; Koukoulis A; Romero-Lopez J; Rodriguez-Perez AI
Front Neuroendocrinol; 2021 Jul; 62():100914. PubMed ID: 33845041
[TBL] [Abstract][Full Text] [Related]
20. Ghrelin mediated neuroprotection - A possible therapy for Parkinson's disease?
Morgan AH; Rees DJ; Andrews ZB; Davies JS
Neuropharmacology; 2018 Jul; 136(Pt B):317-326. PubMed ID: 29277488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
